

WAVEDATA COMMERCIAL BULLETIN

This bulletin now goes out to 5700+ people.

Wavedata's bulletin is a free-of-charge service, if you have any colleagues that would like to receive the bulletin please let us know.

As always, please contact us if you require additional information or if we can be of further assistance regarding products you would like to see in our database.

If you would like to add or suggest any articles or comments, please let us know by the 19th of next month, as the next bulletin will be issued on 26th October 2022.

If this is of interest to you, or you have preferences on what products you would like to see please email: bulletin@wavedata.co.uk

You can view all copies of the Bulletin at www.wavedata.co.uk



GSK SNAPS UP SPERO ANTIBIOTIC

Not influenced by the FDA's decision earlier this year not to approve the drug for adults with complicated urinary tract infections (cUTI), GSK is paying \$66 million upfront to license rights to Spero Therapeutics' novel antibiotic tebipenem Hbr.

The big pharma is paying \$66 million upfront for rights to tebipenem in all regions, except Japan and some other Asian countries

Tebipenem is the first oral drug in the carbapenem antibiotic class to reach late-stage development and, despite the desperate need for new antimicrobials, was turned down in June by the FDA, which said another clinical trial would be required to support approval.

To read more, click the link below:

www.pharmaphorum.com

FAKE BLOOD PRESSURE MEDICINES IN ODISHA MARKET (INDIA)

In the latest development in the seizure of fake drugs in Cuttack, the Commissionerate Police claimed to have achieved major success with the identification of two traders, who had supplied spurious blood pressure medicines to different drug wholesale points.

A special team of Commissionerate Police with help of Gaya Police are conducting raids at various locations in Bihar.

The police have already identified traders involved in the spurious drugs case. We are trying to reach where the fake drugs were procured. The investigation is underway, the DCP told reporters.

To read more, click the link below:

www.hindustantimes.com

AMAZON'S \$3.9B ONE MEDICAL PURCHASE IS BEING REVIEWED

Announced in July, Amazon's acquisition would provide nearly 200 clinics, over 8,000 customers and a trove of member data.

The online retailer has also already begun to unwind Amazon Care, its in-house take on hybrid primary and urgent care (One Medical)

The Federal Trade Commission is reviewing Amazon's \$3.9 billion acquisition of primary care provider One Medical.

To read more, click the link below:

www.fiercehealthcare.com



CHINA APPROVES WORLD'S FIRST INHALED COVID VACCINE

China has become the first country to green-light an inhaled Covid-19 vaccine, paving the way for the potential use of the needle-free product in the country, where suppressing the spread of Covid-19 remains a top priority.

The product, known as Convidecia Air, delivers a vaccine dose through a puff of air from a nebulizer that is then inhaled by mouth. CanSino's injected Convidecia Covid-19 vaccine is already in use in China and has been approved in a handful of other countries.

According to a database maintained by the World Health Organization (WHO), CanSino's new product is one of two specifically "inhaled" vaccines that had reached clinical phase development, as several companies worldwide research innovative ways to deliver Covid-19 protection via the nose and mouth.

To read more, click the link below:

www.edition.cnn.com

BGMA UPDATE AND SURVEY ON ELECTRONIC PATIENT INFORMATION LEAFLETS

Since the beginning of the year, the BGMA have been working with the ABPI, the PAGB, the Sustainable Medicines Partnership, NHS and patient group stakeholders to develop a proposal for ePILs. They have also discussed the topic with the MHRA.

Several things have emerged so far:

- There is probably a minimum 24-month wait before the legal changes can be made in Parliament to allow ePILs to replace paper PILs
- A major engagement campaign will be needed to persuade decision-makers and stakeholders (in Parliament, Government, the MHRA, the NHS, DHSC, and clinicians and patient groups) that such a move would be safe, beneficial to patients and not disadvantage any groups.
- Medicines provided in different care settings raise very different issues re ePILs. For instance, a medicine solely administered by clinicians in a hospital is very different to an over-the-counter medicine bought in a supermarket.
- Potential ePIL solutions vary greatly in their complexity (and potential cost), from a simple web page reproducing the content of a printed PIL, to potentially customised rich video and audio content

The plan will be finalised at a workshop on October 21 in central London to which BGMA member companies will be invited.

If you are interested in being involved in the BGMA's work with ABPI and PAGB to bring in electronic PILs please email sustainability@abpi.org



LACK OF SPECIALIST DOCTORS IN IRELAND

Due to a shortage of specialist doctors, patients' safety is being put at risk. Doctors' roles are not being filled and a significant number of medics quit last year due to burn-out and bullying.

The Irish Medical Council's annual review has, for the first time, linked recruitment challenges directly to patient safety.

They warned 34.9% of doctors are now registered in the "General Division" while at the same time specialist roles are not being filled, which has implications for patient safety.

To read more, click the link below:

www.irishexaminer.com


MARKET PRICE OF A GENERIC PRODUCT

When the market price of a generic product declines to a point where manufacturers can no longer make a profit, they may decide to cancel or not commission the next batch of stock. Consequently, the price goes up as stock availability in the market declines.

These trigger points (low prices which result in manufacturer withdrawal) are highly variable between products, so in some products it can be 50% of the Drug Tariff price, whereas in other cases it can be only 10%. This could reflect the cost of manufacture and other financial factors.

However there is some consistency within products, for example, in the case of 'Losartan Tabs 100mg 28' the low price which triggers the manufacturers to leave and a price spike to happen, tends to be between 50 – 65% of the English Drug Tariff.

In the case of 'Mycophenolate Caps 250mg 100', the trigger points are around 14% of the Drug Tariff price, which suggests that the cost of manufacture for Mycophenolate is considerably lower than Losartan.



PRICE WATCH UK

ARIPIPRAZOLE LEADS A SLEW OF UK PRICE RISES IN A DYNAMIC AUGUST

Aripiprazole led the steepest UK generic price rises in August 2022, a hugely dynamic month that saw treble-digit percentage price increases for a number of molecules, according to the latest figures from WaveData.

In any given month, a treble-digit percentage price rise would likely be enough to place a UK generic product at – or at least near – the top of our regular list of the month's eight Biggest Risers.

To see more go to www.generics.pharmaintelligence.informa.com and view our article from this month's Generics Bulletin.
www.generics-bulletin.com

Generics Bulletin 
Informa Pharma Intelligence

WAVEDATA'S TOP 20 SEARCHED FOR PRODUCTS IN SEPTEMBER 2022

According to WaveData, these were the most commonly investigated products in searches of the online pricing data Wavedata Live accessed through www.wavedata.co.uk/login.

Both UK and PI prices were viewed for each product, giving some indication of where the focus was to September 2022. WaveData prices in the top 20 articles are averages.

Product	Jun-22	Jul-22	Aug-22	Sep-22
Alendronate Tabs 70mg 4	£0.87	£10.58	£12.48	£10.49
Metformin Tabs 500mg 28	£0.26	£0.39	£0.46	£0.40
Fluoxetine Caps 20mg 30	£0.40	£0.79	£1.40	£1.49
Ezetimibe Tabs 10mg 28	£0.90	£1.02	£2.01	£2.01
Citalopram Tabs 10mg 28	£0.45	£0.77	£1.96	£1.73
Citalopram Tabs 20mg 28	£0.56	£1.67	£3.03	£3.03
Omeprazole Caps 20mg 28	£0.42	£0.40	£0.40	£0.39
Clopidogrel Tabs 75mg 28	£0.93	£0.88	£0.99	£0.97
Lercanidipine Tabs 20mg 28	£8.83	£8.71	£8.64	£8.19
Risedronate Sodium Tabs 35mg 4	£1.55	£4.07	£5.12	£6.28
Amlodipine Besilate Tabs 5mg 28	£0.26	£0.33	£0.47	£0.45
Gliclazide Tabs 80mg 28	£0.43	£0.48	£0.59	£0.66
Allopurinol Tabs 100mg 28	£0.38	£0.42	£0.49	£0.48
Sertraline Tabs 100mg 28	£0.79	£0.76	£0.87	£0.90
Amlodipine Besilate Tabs 10mg 28	£0.29	£0.34	£0.48	£0.45
Amoxicillin Caps 500mg 21	£1.32	£1.46	£1.66	£1.71
Amitriptyline Tabs 10mg 28	£0.24	£0.24	£0.28	£0.25
Aciclovir Tabs 400mg 56	£2.71	£2.98	£3.23	£2.91
Finasteride Tabs 5mg 28	£0.75	£0.91	£2.07	£4.50
Losartan Tabs 100mg 28	£2.54	£2.08	£1.79	£1.73



FUTURE EVENTS

Organizer	Date	Venue	a/t
The NHS in Crisis: Can Industry Support Service Survival?	5th Oct 22	Online	http://ow.ly/y3LF50KUm2
EMIG Northern Ireland Special Interest Group Webinar	5th Oct 22	Online	jill.payne (a/t) emig.org.uk
Drug Repurposing for Rare Diseases 2022	10th Oct 22	London	https://www.rarebeacon.org/drug-repurposing-conference/
EMIG Wales Special Interest Group webinar	11th Oct 22	Online	jill.payne (a/t) emig.org.uk
The Scotland Manufacturing & Supply Chain Expo	13th Oct 22	Glasgow	https://www.manufacturingexposcotland.com/register/
Managing Whistleblowing compliance and risks in the life sciences	17th Oct 22	London	https://vwwlegal.zoom.us/webinar/register/WN_a-7wN1b4R7WOLNEUb_kpFw
Priorities for tackling overprescribing in the NHS	18th Oct 22	Online	https://www.westminsterforumprojects.co.uk/book/Overprescribing-22
NHS Clinical Commissioners & NAO	20th Oct 22	Online	https://www.westminsterforumprojects.co.uk/book/NHS-Procurement-2022
EMIG HR Group Development Workshop	20th Oct 22	Online	drjim.golby (a/t) applied-driving.com
HDA Annual Conference	3rd Nov 22	Online	jill.payne (a/t) emig.org.uk
Macmillan Cancer Support & UK National Screening Committee - WHF policy conference	7th Nov 22	Online	https://www.westminsterforumprojects.co.uk/book/Cancer-22
EMIG Annual Parliamentary Dinner	7th Nov 22	London	jill.payne (a/t) emig.org.uk
Social Care Wales	9th Nov 22	Online	https://www.policyforumforwales.co.uk/book/PFW-Social-Care-22
Next steps for digital health and social care	15th Nov 22	Online	https://www.westminsterforumprojects.co.uk/book/Digital-Health-2022
Next steps for addressing clinical negligence claims in England	22nd Nov 22	Online	https://www.westminsterforumprojects.co.uk/book/Clinical-Neg-22
Next steps for mental health in England and priorities for the mental health and wellbeing plan	29th Nov 22	Online	https://www.westminsterforumprojects.co.uk/book/Mental-Health-22
Next steps for genomics in the UK	13th Dec 22	Online	https://www.westminsterforumprojects.co.uk/book/Genomics-22

CLICK THE LINKS TO OPEN

THANK YOU FOR YOUR TIME

